C1494

Carmofur

≥98% (HPLC), powder

• Synonym(s): 1-Hexylcarbamoyl-5-fluorouracil, HCFU
• Empirical Formula (Hill Notation): C₁₁H₁₆FN₃O₃
• CAS Number: 61422-45-5
• Molecular Weight: 257.26
• NACRES: NA.77
• PubChem Substance ID: 329774890
• UNSPSC Code: 12352200
• MDL number: MFCD00866284
• Assay: ≥98% (HPLC)
• Form: powder

Properties

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to off-white
• solubility: DMSO: >15 mg/mL
• storage temp.: 2-8°C
• SMILES string: CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O
• InChI: 1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)
• InChI key: AOCCBINRVIKJHY-UHFFFAOYSA-N

Description

Application

Carmofur has been used as an inhibitor of acid ceramidase to study its effects on glucosylsphingosine (GlcSph) production in human embryonic kidney 293T (HEK293T) cells. It has also been used as an inhibitor of acid ceramidase to study its effects on acid‐mediated hydrolysis of ceramide which kicks-in consumption and the generation of sphingosine [1].

Biochem/physiol Actions

Carmofur is a derivative of fluorouracil, an antimetabolite used as an antineoplastic agent.

Carmofur is an antineoplastic agent and a flurorouracil analog.

Carmofur acts as an inhibitor of fatty acid amide hydrolase (FAAH), N-acylethanolamine acid amidase (NAAA) and acid ceramidase (ASAH1). Carmofur has a therapeutic activity against colorectal and cervical cancer. It can inhibit the severe acute respiratory syndrome (SARS)-CoV-2 main protease (M^pro) in vitro.

Safety Information

• pictograms: GHS06,GHS08
• signalword: Danger
• hcodes: H301,H361
• pcodes: P201 - P301 + P310 + P330
• Hazard Classifications: Acute Tox. 3 Oral - Repr. 2
• Storage Class: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable